Adipotide, also written FTPP for its prohibitin-targeting peptide structure, is an experimental compound with no approved human use. It appears in the formulary and in patient questions because it circulates in online body-composition communities, not because it has a clinical role. Its story is a useful lesson in why mechanistic elegance does not make a drug.
This guide situates Adipotide within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
What is adipotide?
Adipotide is a synthetic peptide with two functional halves joined together. One half is a homing sequence that binds prohibitin, a protein expressed on the surface of blood vessels that specifically supply white adipose tissue. The other half is a proapoptotic sequence that triggers programmed cell death once the molecule is internalized.
The design intent is to deliver a cell-killing payload selectively to the vasculature feeding fat tissue. Starve the blood supply, and the fat tissue it supports regresses. It is a genuinely clever piece of targeting chemistry.
What the animal studies showed
In obese rhesus monkeys, adipotide produced substantial reductions in body weight and body fat over a short treatment course, along with improvements in insulin sensitivity. Those results attracted considerable attention when published.
The same studies identified the problem. The compound caused dose-dependent kidney toxicity, with evidence of renal injury on histology. The likely explanation is that prohibitin is not expressed exclusively on adipose vasculature — the renal system takes up the compound as well, and the proapoptotic payload does there exactly what it was designed to do elsewhere.
That is the core failure. The targeting was not selective enough to confine a cell-killing agent to its intended tissue, and a weight-loss drug that damages kidneys has an untenable risk-benefit balance for a chronic, non-lethal condition.
Regulatory status and the safety question
Adipotide has not been approved by the FDA or any comparable authority. It did not complete a successful human development program. It is not an eligible compounding substance, and there is no legitimate clinical supply.
Material sold online under this name is a research chemical of unverified identity, purity and concentration. Given a mechanism built specifically around triggering cell death, the consequences of an impure or misdosed product are not theoretical.
The straightforward clinical message for any patient asking is that this is a compound whose animal studies revealed organ toxicity, which is precisely why it is not a medication. Patients seeking weight-management treatment should be directed to the agents that completed the regulatory path, discussed in our weight loss medications overview.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering peptide mechanisms and the evidence hierarchy, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →